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Abstract
Background: The purpose of this study was to identify candidate metastasis suppressor genes
from a mouse allograft model of prostate cancer (NE-10). This allograft model originally developed
metastases by twelve weeks after implantation in male athymic nude mice, but lost the ability to
metastasize after a number of in vivo passages. We performed high resolution array comparative
genomic hybridization on the metastasizing and non-metastasizing allografts to identify
chromosome imbalances that differed between the two groups of tumors.
Results:  This analysis uncovered a deletion on chromosome 2 that differed between the
metastasizing and non-metastasizing tumors. Bioinformatics filters were employed to mine this
region of the genome for candidate metastasis suppressor genes. Of the 146 known genes that
reside within the region of interest on mouse chromosome 2, four candidate metastasis suppressor
genes (Slc27a2, Mall, Snrpb, and Rassf2) were identified. Quantitative expression analysis confirmed
decreased expression of these genes in the metastasizing compared to non-metastasizing tumors.
Conclusion:  This study presents combined genomics and bioinformatics approaches for
identifying potential metastasis suppressor genes. The genes identified here are candidates for
further studies to determine their functional role in inhibiting metastases in the NE-10 allograft
model and human prostate cancer.
Background
Prostate cancer (PCa) is a heterogeneous disease and the
ability to predict its clinical outcome is limited. Numer-
ous chromosomal abnormalities and alterations in gene
expression have been reported in PCa, yet identification
of many of the specific genes that drive the progression of
these tumors is still lacking. The finding of the TMPRSS2/
ETS fusion and the overexpression of ETS transcription
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family members in the majority of PCa illustrates the suc-
cess of utilizing a bioinformatics approach to gene discov-
ery [1], but the consequences of many other recurrent
acquired genomic alterations remain to be elucidated.
Studies of human PCa are hindered by the biologic and
genetic heterogeneity of this disease not only between
individuals, but also within a given individual. Geneti-
cally engineered mouse models of PCa provide an in vivo
experimental system in which tumors with the same
underlying etiology can be sampled during the course of
progression at defined time points. The LPB-Tag mouse
model of prostate cancer is one such model that has been
well characterized [2-4].
We have previously described the establishment of an
allograft (NE-10) from a primary prostate tumor from the
LPB-Tag mouse model that consistently metastasized by
12 weeks after transplantation in nude mice in early pas-
sages [4]. Conventional cytogenetic analysis of the NE-10
allograft revealed numeric and structural chromosome
abnormalities, including a deletion of distal chromosome
2 that was consistently present over multiple in vivo pas-
sages of the allograft in nude mice [4]. A similar chromo-
some 2 deletion has also been described in a mouse
model of acute promyelocytic leukemia [5]. After repeated
in vivo passages, the NE-10 allograft eventually lost the
ability to metastasize. In this study, we have taken advan-
tage of the differential metastasizing behavior of the NE-
10 allograft, arising from the same original tumor, to
screen the genome for candidate genes that play a role in
metastasis. High resolution genomic technology, com-
bined with novel bioinformatics approaches, enabled us
to identify different regions of chromosome imbalances
between the two allograft lines, and to propose candidate
metastasis suppressor genes within a region of chromo-
some 2 that was found to harbor a larger deletion in met-
astatic compared to non-metastatic tumors.
Methods
NE-10 allograft model
The 12T-10 line of the LPB-Tag mouse model of prostate
cancer was generated using a transgene that consists of the
rat probasin promoter driving the SV40 large T antigen
with deletion of the small T antigen [3]. These mice
develop low-grade and high-grade prostatic intraepithe-
lial neoplasia at 2-5 month of age, with progression to
invasive and metastatic, high-grade, androgen-independ-
ent carcinoma demonstrating neuroendocrine differentia-
tion at 6-14 months of age. A primary prostate tumor
from the ventral prostate of a 12T-10 transgenic mouse
was used to establish an allograft model by implantation
subcutaneously in male athymic nude mice [4]. After 18
weeks, the allograft was passaged to another male nude
mouse and the process was repeated to establish the NE-
10 line [4]. Initial passages in all mice developed grossly
visible metastases to liver and micrometastases to lung by
twelve weeks after implantation. All metastases from the
allografts were histologically similar to the metastasis seen
in the 12T-10 mice. Later allograft passages showed histo-
logically identical features to the early passages; however,
fewer allografts developed metastases. By passage 15, met-
astatic potential was completely lost, at least up to the
point where it was no longer feasible to maintain the mice
due to the size of the subcutaneous tumors. Tumors con-
sisting of non-metastasizing subcutaneous allografts
(SQnon-met), metastasizing subcutaneous allografts
(SQmet), and liver metastases (LiverMet) were collected
at 12 weeks post-implantation and snap-frozen for array
CGH. All procedures involving mice were approved by the
Vanderbilt University Medical Center and Fred Hutchin-
son Cancer Research Center Institutional Animal Care and
Use Committees.
Array comparative genomic hybridization (CGH)
Array CGH was initially carried out using mouse bacterial
artificial chromosome (BAC) arrays produced by the
Genomics Shared Resource, Fred Hutchinson Cancer
Research Center as described [6]. The mouse BAC clone
set was obtained from A. Bradley, Wellcome Trust Sanger
Institute [7] and provides an average resolution of 1 Mb.
DNA was isolated using the Gentra Puregene genomic
DNA purification kit (Qiagen, Valencia, CA). For the BAC
arrays, three SQnon-met tumors (passage 19), three
SQmet (passages 4, 9, and 12), and four LiverMet (two
each from passages 9 and 12) were analyzed. One
matched SQmet and LiverMet from the same nude mouse
at passage 9 was included in the analysis. Pooled DNA
obtained from normal kidney from four different CD-1
males was used as a reference. DNA labeling, hybridiza-
tion, scanning, and data analysis was performed as
described previously [6].
Array CGH was repeated on a subset of two tumors each
from the SQnon-met and LiverMet groups using the Agi-
lent mouse 105K oligonucleotide CGH arrays. These
arrays were designed using UCSC mm7 (NCBI build 35,
August, 2005), and have an average probe spacing of 15
Kb. One ug of RsaI/AluI digested DNA was labeled with
either Cy3 or Cy5 using the BioPrime Array CGH genomic
labeling system (Invitrogen Corp., Carlsbad, CA). Approx-
imately 4 ug each of Cy5 labeled test (tumor) DNA and
Cy3 labeled reference (normal female C57Bl/6 liver) DNA
was combined with 25 ug of mouse Cot-1 (Invitrogen
Corp.), Agilent 10× blocking agent and 2× hybridization
buffer (Agilent Technologies, Santa Clara, CA) to a final
volume of 260 ul. Hybridization and washes were carried
out according to the Agilent oligo array-based CGH proto-
col v. 4.0. Scanning was performed on an Agilent scanner
and data extraction was carried out using Agilent feature
extraction software v.9.1, employing linear and Lowess
normalization. Results were analyzed and chromosome
plots generated using CGHanalytics software v. 6.0. The Z-Molecular Cytogenetics 2009, 2:18 http://www.molecularcytogenetics.org/content/2/1/18
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score algorithm with the threshold set at 2.0 and a 2 Mb
window was used for determining gains and losses. The
LPB-Tag tumors were generated on an outbred CD-1 back-
ground, and we did not have non-neoplastic DNA availa-
ble from the mouse whose tumor was used to establish
the allograft. As C57Bl/6 reference DNA was used for the
oligonucleotide array CGH experiments, gains and losses
smaller than 2 Mb were ignored in order to avoid mistak-
ing benign copy number variants between mouse strains
from acquired copy number alterations in the tumors.
To compare array CGH profiles between the different
groups of tumors, the Differential Gene locus MAPping
software (DIGMAP version 2.0) was used to analyze array
CGH data sets [8]. Using the default parameters specified
in the program, DIGMAP displayed array CGH data as a
heat map based on log2 ratio between test and reference
DNA for each tumor. The chromosome regions with sig-
nificantly different log2 ratios were marked as differential
flagged regions (DFRs) by direct visualization and compu-
tational screening using a T-test based sliding window
(TTSW) analysis. For this analysis, a window size of 40
genes was used and DFRs represent regions greater than 3
standard deviations from the whole genome average T
score.
Expression arrays
Expression arrays were performed on two SQnon-met
tumors (passages 11b, 18c) and four SQmet tumors (pas-
sages 2, 5, 14a, 14c). Allograft passages were labeled a, b,
c, etc. when the same graft passage was implanted into
more than one mouse. As a control, mouse reference RNA
from two postnatal day 1 mice was pooled. RNA was iso-
lated using the RNeasy kit (Qiagen Valencia CA), includ-
ing treatment with DNase. RNA was quantified using a
NanoDrop (ThermoScientific). All samples analyzed had
a A260/230 ratio greater than 1.8. RNA quality was ana-
lyzed on an Agilent 2100 BioAnalyzer. All samples ana-
lyzed had a 28S peak greater than 18S peak, or an RIN
number greater than 7. The 16 k mouse arrays used for the
study were printed at the Vancouver Microarray Facility
using Operon's 16 K 70 mer oligomers printed on ami-
nosaline slides. Ten ug of total RNA was labeled using
Genisphere's Dendrimer 350 expression array detection
kit for microarrays according to the manufacturer's proto-
col. Samples were co-hybridized with ten ug of the above
described mouse reference RNA. Arrays were pre-hybrid-
ized in 5 × SSC, 0.1% SDS and 0.2% BSA for 45 minutes.
Pre-hybridization buffer was washed off with 3 × 30 sec-
ond water washes and a 2 minute wash in isopropanol.
Slides were spun dry at 2000 rpm for 4 minutes. The sam-
ples were applied to arrays containing 60 × 22 mm lifter
slips (Erie Scientific). Slides were subsequently treated as
described in the Genisphere Array 350 expression array
detection kit for microarrays. Arrays were scanned on a
Axon 4200AL scanner (Molecular Devices). Image inten-
sities were extracted using ImaGene V8.0 software (Bio-
Discovery).
To identify chromosome regions that demonstrate differ-
ential gene expression between metastatic and non-meta-
static tumors, expression array datasets were analyzed
between SQnon-met and SQmet mice using DIGMAP as
described above for array CGH data. A TTSW genome scan
was also performed as described above.
Identification of candidate metastasis suppressor genes in 
chromosome 2 DFR
A total of 146 known genes in the chromosome 2 differ-
ential region of deletion (DFR) between metastatic and
non-metastatic tumors (nucleotides 122,316,740-
139,585,560) were retrieved from the UCSC mm7 data-
base http://genome.ucsc.edu. Two bioinformatics filters
were designed to determine which of these 146 genes
might function as candidate metastasis suppressor genes.
A functional filter utilized the Gene Ontology (GO) data-
base http://www.geneontology.org, PubMed http://
www.ncbi.nlm.nih.gov/PubMed/, and Ingenuity Pathway
Analysis (IPA, http://www.ingenuity.com) to evaluate the
146 genes for potential metastasis suppressor function. A
parallel filter employing our recently developed human
cancer expression signature database (EXALT) was used to
independently validate the genes as candidate metastasis
suppressors in silico [9]. A weighted score was assigned to
each gene for both filters (see Additional file 1).
Quantitative reverse transcription (RT)-PCR
Total RNA was isolated using the RNeasy Mini kit (Qia-
gen, Valencia, CA) according to the manufacturer's proto-
col, including the recommended DNase treatment step.
Three ug of RNA was reverse transcribed using the Reac-
tionReady First Strand cDNA Synthesis Kit (SuperArray
Bioscience Corp., Frederick, MD). Primer sets for mouse
Hprt1,  Slc27a2,  Mal,  Snrpb, and Rassf2  were purchased
from SuperArray (proprietary primers, sequence not dis-
closed).
PCR reactions were carried out in triplicate in a 25 μL vol-
ume using SYBR Green Master Mix (SuperArray). The
standard two-step amplification with an annealing tem-
perature of 60°C was performed in an ABI 7900 PCR
machine.  Hprt1  was chosen as an endogenous control
gene because Hprt1 expression values were stable among
test samples in the microarray expression data set.
To allow for a comparison between samples and the two
groups, quantities of all target genes in the test samples
and a common reference RNA (Mouse XpressRef Univer-
sal Total RNA, SuperArray) were normalized to the corre-
sponding  Hprt1  levels. Relative expression levels (fold
changes) were calculated using the relative standard curve
method as outlined in the manufacturer's technical userMolecular Cytogenetics 2009, 2:18 http://www.molecularcytogenetics.org/content/2/1/18
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manual (SuperArray). A standard curve was generated
using the fluorescent data from 10-fold serial dilutions of
the common reference RNA sample. Four tumors each
from the metastasizing and non-metastasizing allografts
were analyzed. Statistically significant differences in
expression between the two groups were determined
using a Student's T-Test.
Results
Differences in copy number alterations between 
metastatic and non-metastatic tumors
Copy number alterations in tumors were identified by
array CGH performed using BAC arrays for all tumors,
and oligonucleotide arrays for a subset of tumors. Array
CGH using both BAC and oligonucleotide platforms
detected multiple gains and losses in both non-metastatic
tumors (SQnon-met) and tumors with metastatic poten-
tial (SQmet and LiverMet). Both array platforms uncov-
ered similar chromosome imbalances, but the
oligonucleotide arrays allowed us to more precisely map
regions of gain and loss. Many copy number alterations
were common to both groups of tumors, including dele-
tions involving regions of chromosomes 1, 2, 3, 4, 8, 13,
16, 17 18, 19, whole chromosome loss of 14, and gains of
chromosome 8 (Figure 1 and Table 1); however, differ-
ences in copy number changes between the tumors with
and without metastatic potential were also uncovered
(Figure 1 and Table 1). One notable difference between
the two groups of tumors was a differential region of dele-
tion in distal chromosome 2. Both the metastatic and
non-metastatic tumors shared a common 27.4 Mb inter-
stitial deletion of distal chromosome 2, from bands F3 to
H3 (139,585,560-167,088,181 bp); however, the meta-
static tumors (LiverMet) showed a larger 45 Mb deletion
(122,316,740-167,088,181 bp) that extended proximally
to band E5 (Figure 2). The non-metastatic tumors showed
clonal heterogeneity for both the larger and smaller dele-
tions, with low-level mosaicism for the larger deletion
(Figure 2 top), but the clone or clones with the larger dele-
tion were enriched in the metastatic tumors (Figure 2 bot-
tom).
Differences in gene expression profiles between metastatic 
and non-metastatic tumors
To obtain differential gene expression profiles between
non-metastatic and metastatic NE-10 tumors, the differ-
ent groups of tumors (SQnon-met, SQmet, and LiverMet)
were profiled using gene expression microarrays and ana-
lyzed by DIGMAP. A T-test sliding window whole genome
scan was performed and plotted by chromosome (see
Additional file 2). Based on this analysis, chromosome 2
had the greatest number of regions showing the largest
difference in gene expression between metastatic (SQmet
and LiverMet) and non-metastatic (SQnon-met) tumors.
A detailed T-test sliding window plot of chromosome 2
revealed the highest DFR expression peak in band H4,
from 179 to 181 Mb (see Additional file 2). This region is
distal to the common region of deletion found in both the
metastatic and non-metastatic tumors. Three other
smaller peaks were also located slightly more centromeric,
from 155 to 168 Mb, within the common region of dele-
tion. Thus, regions of differential gene expression between
metastatic and non-metastatic tumors were located both
within and distal to the common chromosome 2 deletion;
however, we were unable to detect any clusters of genes
that demonstrated down-regulation in the metastatic
compared to the non-metastatic tumors. There were also
no significant differences in gene expression detected in
the differential region of deletion on chromosome 2
between the metastatic and non-metastatic tumors.
Identification of candidate metastasis suppressor genes in 
chromosome 2 differentially deleted region
Metastasis suppressor genes are expected to show inactiva-
tion or decreased activity in metastatic tumors because of
Heat map of oligonucleotide array CGH results Figure 1
Heat map of oligonucleotide array CGH results. 
Array CGH results are partitioned by chromosome number 
and clustered by probe location in the chromosomes. The 
length of each chromosome bar is based on the total number 
of probes for that chromosome present on the array. Within 
each chromosome bar, each row represents a separate NE-
10 tumor, and the non-metastatic tumors (SQnon-Met) are 
separated from the metastatic tumors (LiverMet) by the 
white line (SQnon-Met above and LiverMet below the line). 
Black represents normal copy number in tumor compared to 
the normal reference; red represents increased copy 
number; green represents decreased copy number. A larger 
interstitial deletion in chromosome 2 can be visualized in the 
metastatic compared to the non-metastatic tumors (blue 
box). Relative loss of the X chromosome in the metastatic 
tumors, and most of the X chromosome in the non-meta-
static tumors, is seen because array CGH for these tumor 
samples was performed using a sex-mismatched (female) ref-
erence DNA. The non-metastatic tumors also show a region 
of copy number gain on the X chromosome.Molecular Cytogenetics 2009, 2:18 http://www.molecularcytogenetics.org/content/2/1/18
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genetic or epigenetic changes that result in loss or down-
regulation of expression. The finding of a differentially
deleted region on chromosome 2, potentially resulting in
loss of a metastasis suppressor gene in the metastatic
tumors, led us to focus on this region for more detailed
analysis. Given that only a subset of genes in the differen-
tially deleted region was represented on the expression
arrays, we employed an informatics approach to identify
all potential candidate metastasis suppressor genes in the
region of interest (chromosome 2 E5-F3; nucleotides
122,316,740-139,585,560). Two parallel bioinformatics
filters were designed to carry out this analysis. Out of a
total of 146 genes in the region of interest, 11 candidate
metastasis suppressor genes were identified based on the
function-based filters, while 22 candidates were identified
using a filter that employed a cancer expression signature
filter using the EXALT database (see Additional file 3). A
final list of four candidate genes (Slc27a2, Mall, Snrpb, and
Rassf2) was chosen based on having the highest total
score.
Chromosome 2 oligonucleotide array CGH plots Figure 2
Chromosome 2 oligonucleotide array CGH plots. 
Chromosome 2 plots are shown for one representative non-
metastatic (SQnon-Met) and one representative metastatic 
(LiverMet) tumor. The normalized log2 ratio is on the Y axis, 
and the chromosome bands are designated on the X axis. 
Copy number gains and losses are designated by the bars 
above or below a log2 ratio of 0, respectively. The shaded 
area reflects the magnitude of the gain or loss. The meta-
static tumors show only the larger chromosome 2 deletion 
(bottom panel), whereas the non-metastatic tumors demon-
strate clonal heterogeneity, with the both the smaller dele-
tion, as well as low-level mosaicism for the larger deletion 
(top panel).
Table 1: Summary of acquired copy number changes identified 
by oligonucleotide array CGH in liver metastases (LiverMet) 
from NE-10 allografts, and in non-metastasizing (SQnon-met) 
NE-10 allografts
Chromosome SQnon-met LiverMet
1 - loss *84525268-103082423 84525268-103082423
2 - loss 139585560-167088181 122316740-167088181
3 - loss 11809017-qter 11809017-qter
4 - loss 3010281-131339250 3010281-131339250
4 - gain N.A. 132282308-149233400
5 - loss 3003879-114937488 N.A.
7 - loss N.A. whole chromosome
8 - gain 8397754-17345126 8397754-17345126
8 - gain 20825979-35687899 20825979-35687899
8 - loss 37627333-qter 37627333-qter
10 - gain 79500370-89346058 N.A.
10 - loss 89748171-qter N.A.
12 - gain 3021012-12590005 N.A.
13 - loss whole chromosome 3015154-60624834
14 - loss whole chromosome whole chromosome
15 - gain 99348507-qter N.A.
16 - loss 3026317-36861999 whole chromosome
17 - loss 3023355-10795310 whole chromosome
17 - loss 29138819-qter whole chromosome
18 - loss 35576728-qter whole chromosome
19 - loss 46971550-qter 46971550-qter
X - gain 145268084-149114686 N.A.
N.A. = not applicable
*Nucleotide sequences are from NCBI build 35Molecular Cytogenetics 2009, 2:18 http://www.molecularcytogenetics.org/content/2/1/18
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Quantitative RT-PCR of 4 candidate metastasis suppressor 
genes in chromosome 2 differentially deleted region
Quantitative RT-PCR for the four candidate metastasis
suppressor genes was performed in tumors with meta-
static potential (SQMet) and tumors without metastatic
potential (SQnon-Met). Metastatic liver tumors were not
analyzed due to the presence of contaminating normal
liver tissue in some of the tumors. All four candidate
metastasis suppressor genes demonstrated decreased
expression in the metastasizing tumors compared to the
non-metastasizing tumors, with Slc27a2 and Snrpb show-
ing statistically significant decreased expression in the
metastasizing tumors (Figure 3).
Discussion
Using high-resolution array CGH, we uncovered multiple
copy number changes common to both the metastatic
and non-metastatic tumors, consistent with a phenotype
of genomic instability in this model. Many of the regions
of loss overlap with frequent losses that have been
observed by conventional CGH and array CGH per-
formed on localized and metastatic human PCa, includ-
ing human 4q22.3-q31.1, 5q21.1-q21.3, 6q15-q16.2,
8p21.1-p23.1, 10q23.1, 10q25.1-q25.3, 13q14.2-q22.1,
16q12.1-q24.3, 18q12.3-q21.1, 18q21.31-q21.32,
18q22.1-q23 [10-12]. Loss of specific tumor suppressor
genes implicated in human PCa, such as Nkx3-1 and Rb1,
was also present in the mouse NE-10 allograft. Other
alterations that are frequently seen in human PCa, such as
loss of PTEN, loss of CDKN1B, and gain of MYC, were not
observed in the NE-10 model.
In addition to copy number alterations common to both
the metastatic and non-metastatic tumors, we also
observed differences in copy number alterations between
these two groups of tumors that could be responsible for
their divergent behavior. These differences included loss
of chromosome 2 (122.3-139.6 Mb), gain of chromo-
some 4 (132.2-149.2 Mb), loss of chromosome 7, loss of
chromosome 16 (36.9 Mb -qter), loss of chromosome 17
(10.8- 29.1 Mb), and loss of chromosome 18 (3.3-35.6
Mb) in the metastatic, but not the non-metastatic tumors.
Our attention was drawn to a differentially deleted region
of chromosome 2 for a number of reasons. First, haploin-
sufficiency or inactivation of metastasis suppressor genes
can occur through deletion. We have also detected distal
chromosome 2 deletions in approximately 35% of meta-
static tumors from multiple independent mice from the
original 12T-10 transgenic line (unpublished data), con-
firming that this is a recurring chromosome abnormality
in tumors from this model. In addition, a similar deletion
of chromosome 2 has previously been reported in a
mouse model of acute promyelocytic leukemia [5]. Also,
the larger region of deletion that is enriched in the meta-
static tumors demonstrates conserved synteny with the
short arm of human chromosome 20 that has been impli-
cated in metastatic PCa [13]. In the mouse model of acute
promyelocytic leukemia, loss of one copy of the Sfpi1
(Pu.1) gene due to the chromosome 2 deletion, and
reduced expression of this gene, have been implicated in
the progression of leukemia in these mice [14]. The Sfpi1
gene is not an obvious candidate metastasis suppressor
gene in the NE-10 allograft model, as the gene maps
approximately 31 Mb centromeric to the proximal chro-
mosome 2 deletion breakpoint in the metastatic tumors.
Cd82  (Kai1) and Cd44, known metastasis suppressor
genes for prostate [15,16], are also located many mega-
bases (~29 Mb and 20 Mb, respectively) proximal to the
chromosome 2 deletion. Expression array analyses that we
performed also did not uncover candidate metastasis sup-
pressor genes within this differentially deleted region;
therefore, we employed a bioinformatics approach to
identify potential candidate genes that may be involved in
the metastatic behavior of these tumors.
The candidate metastasis suppressor genes in the differen-
tial region of deletion of chromosome 2 that we identi-
fied, based on prior evidence of metastasis suppressor
function and down-regulation in cancer, consisted of
Relative expression levels between metastatic and non-meta- static NE-10 tumors by RT-PCR Figure 3
Relative expression levels between metastatic and 
non-metastatic NE-10 tumors by RT-PCR. The X-axis 
shows four candidate metastasis suppressor genes and the Y-
axis shows relative fold change (log2 based) between SQMet 
and SQnonMet NE-10 tumors (top panel). The relative 
expression levels are designated by the height of bars, and 
standard deviation error bars are in the direction of SQMet 
samples. An asterisk indicates significantly decreased expres-
sion in SQMet samples (P < 0.05). The corresponding 
genomic locations of the four candidate genes on mouse 
chromosome 2, and the regions of conserved synteny in 
human, are shown below.Molecular Cytogenetics 2009, 2:18 http://www.molecularcytogenetics.org/content/2/1/18
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Slc27a2, Mall, Snrpb, and Rassf2. All of these genes demon-
strated decreased expression in the metastasizing com-
pared to the non-metastasizing NE-10 tumors by
quantitative RT-PCR. MALL (MAL, T-cell differentiation
protein) is a raft-associated integral membrane protein
that is involved in membrane trafficking processes.
Expression of the MAL protein has been demonstrated in
specific types of normal epithelial cells throughout the
respiratory system, the gastrointestinal tract, and the gen-
itourinary tract, including strong expression in the ductal
and acinar cells of the prostate [17]. Loss of or decreased
MALL expression, sometimes as the result of DNA meth-
ylation of the promoter region, has been found in a vari-
ety of benign and malignant epithelial tumors compared
to their normal epithelial counterparts, consistent with a
role for this protein in tumor suppression [17-21]. Fur-
thermore, MAL has been shown to enhance apoptosis
through the Fas pathway, and suppress tumorigenicity,
invasion, and motility [21]. Although loss or decreased
MALL expression has not been evaluated in human pros-
tate cancer, the expression of this protein in normal pros-
tate epithelium and its ability to suppress invasion and
motility render it a biologically plausible metastasis sup-
pressor gene for prostate cancer.
SLC27a2 encodes a protein that is an isozyme of the long-
chain fatty-acid-coenzyme A ligase family, and as such
plays a role in lipid biosynthesis and fatty acid degrada-
tion. It may also be involved in translocation of long-
chain fatty acids across membranes [22]. Long-chain fatty
acids participate in many cellular functions and have been
implicated as modulators of carcinogenesis, partly
through their ability to activate peroxisome proliferator-
activated receptors (PPAR). There is evidence that PPAR
gamma regulates prostatic epithelial differentiation and
may restrict epithelial proliferation; therefore, it is possi-
ble that decreased expression of Slc27a2 in the NE-10 allo-
graft model could alter the tumor suppressor activity of
PPAR gamma and contribute to metastatic behavior.
With regard to RASSF2  and  SNRPB, Goodzari and co-
workers found evidence for a prostate cancer metastasis
suppressor gene on the short arm of human chromosome
20 [13]. The differential region of chromosome 2 deletion
in metastatic compared to non-metastatic tumors in the
NE-10 model shows conserved synteny with a region of
human 20p. RASSF2 and SNRPB also map to the short
arm of human chromosome 20, although they are telom-
eric to the most likely metastasis suppressor region of 20p
(20p11.23-p12) that was proposed [13]. SNRPB encodes
a protein that is one of several nuclear proteins that are
found in common among U1, U2, U4/U6, and U5 small
ribonucleoprotein particles (snRNPs). These snRNPs are
involved in pre-mRNA splicing. RASSF2 (RAS association
domain family 2) is a negative effector of Ras and has
been implicated as a tumor suppressor gene in a number
of other forms of epithelial cancer, such as colon, gastric,
breast, and lung carcinoma [23-25]. The mechanism of
inactivation of RASSF2 described in these tumors is aber-
rant promoter methylation, primarily in early tumors. In
addition, inactivation of the A isoform of RASSF2 by pro-
moter methylation has been found to correlate with a
higher frequency of lymph node metastases in patients
with nasopharyngeal carcinoma [26].
In summary, using an approach based on bioinformatic
filters applied to array CGH data on a divergent metasta-
sizing and non-metastasizing mouse model of PCa, we
have identified genes that are biologically plausible
metastasis suppressor genes. Our studies have identified
an association between deletion with decreased expres-
sion of these genes and the metastasizing NE-10 model,
suggesting a biological role for these genes in the meta-
static process. We believe the divergence in behavior of the
allograft can be attributed to clonal heterogeneity, with
both metastasizing and non-metastasizing clones present
in early allograft passages, but with selection for a non-
metastasizing clone or clones after multiple in vivo pas-
sages. This selection could be due to preferential subcuta-
neous growth of the non-metastasizing compared to the
metastasizing component of the allograft, such that over
time, a larger and larger percentage of the allograft con-
sists of the non-metastasizing population. It is possible
that the clone or clones with the larger chromosome 2
deletion are enriched in the metastatic tumors because the
differentially deleted region itself is responsible for the
metastatic behavior, either alone or in combination with
other genetic alterations, or that the larger deletion is sim-
ply a marker for a clone that is selected for because of the
presence of some other alteration that confers metastatic
potential. Additional studies are needed to prove that a
gene or genes within the differentially deleted region of
chromosome 2 are responsible for suppression of meta-
static behavior.
Conclusion
We have taken advantage of a mouse allograft model of
PCa (NE-10) with divergent metastasizing and non-
metastasizing behavior to identify regions of the genome
that potentially harbor metastasis suppressor genes. Using
a combination of genomics and bioinformatics
approaches, we identified candidate genes from a differ-
entially deleted region on mouse chromosome 2 between
the metastasizing and non-metastasizing allograft lines.
The genes presented here are candidates for further studies
to determine their functional role in inhibiting metastases
in the NE-10 allograft model and human PCa.
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